Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
It is probably fair to say that readers should expect little in the way of revolutionary new information affecting the management of prostate cancer from this year’s annual meeting of the American Urological Association (AUA). However,
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: active surveillance, imaging, Management, screening | 4 Comments »
The National Comprehensive Cancer Network has updated its prostate cancer management guidelines to give a category 1 recommendation for clinical use of sipuleucel-T (Provenge) in the treatment of selected patients.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: guidelines, NCCN, Provenge, sipuleucel-T | Leave a Comment »
According to a report from Reuters and a media release on the Amgen web site, the European Medicines Agency (EMEA) has approved denosumab (Prolia®) for marketing in Europe.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: denosumab, Prolia | 2 Comments »
A recent article in Urology suggests that patients in the SEARCH database who would theoretically have been eligible for active surveillance (AS) for low-risk prostate cancer were actually at increased risk for recurrence if they were of older age, obese, or had been exposed to Agent Orange.
Filed under: Management, Treatment | Tagged: active surveillance, outcome, Veterans Administraton | 3 Comments »
The Prostate Cancer Foundation (PCF) has announced plans for a National Proactive Surveillance Network (NPSN) designed to reduce overtreatment of prostate cancer patients to better direct resources to those patients with more aggressive, life-threatening varieties of this disease.
Filed under: Uncategorized | Tagged: active surveillance, National Proactive Surveillance Network | 2 Comments »
Oncology Times has just completed a five-part series of what appear to be objective and impartial articles on proton beam radiation therapy (PBRT) — as a form of treatment for many types of cancer, not just prostate cancer.
Filed under: Management, Treatment | Tagged: center, proton, radiation, therapy | 4 Comments »
Yesterday, GTx, Inc. announced initial results of their Phase III clinical trial designed to test the effect of toremifene 20 mg on the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HG-PIN).
Filed under: Prevention | Tagged: HG-PIN, Prevention, toremifine | Leave a Comment »
There are a couple of interesting new commentaries that discuss the idea of using 5α-reductase inhibitors to prevent prostate cancer (and other agents to prevent breast cancer).
Filed under: Prevention | Tagged: dutasteride, finasteride, Prevention | 1 Comment »
A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bisphosphonate, bone, hormone, loss, risedronate, therapy, turnover | Leave a Comment »
At urology clinics in three states in the USA, prostate cancer patients were asked, after diagnosis but before treatment, about their likes and dislikes of five common treatment options.
Filed under: Management, Treatment | Tagged: choice, option, Treatment | 4 Comments »
We note that the second Phase III clinical trial of abiraterone acetate — in asymptomatic or mildly symptomatic patients with metastatic, castration-resistant prostate cancer (mCRPC) who have not had either chemotherapy or ketoconazole therapy — is now fully enrolled (as of last Friday).
Filed under: Drugs in development, Uncategorized | Tagged: abiraterone, trial | 2 Comments »
The recommendations of the U.S. Preventive Services Task Force (USPSTF) about cancer screening continue to come under direct political fire from Capitol Hill — and this is probably not a very constructive idea.
Filed under: Diagnosis, Prevention, Risk | Tagged: screening, testing, USPSTF | 1 Comment »
We know that statin therapy appears to lower risk for prostate cancer and to increase the overall survival of men diagnosed with prostate cancer. However, what we don’t know (yet) is whether statin therapy during and after specific types of treatment has prostate cancer-specific outcome benefits.
Filed under: Management, Treatment | Tagged: EBRT, external beam radiation therapy, outcome, statin | Leave a Comment »
There’s a new article in the radiation therapy literature suggesting a direct correlation between prostate volume and risk for severe, acute, genitourinary toxicity when prostate cancer patients with large-volume prostates are treated with intensity-modulated radiation therapy (IMRT).
Filed under: Management, Treatment | Tagged: genitourinary toxicity, IMRT, risk, volume | Leave a Comment »
The American Society for Radiation Oncology (ASTRO) has issued a draft technical report from the Evaluation Subcommittee of their Emerging Technologies Committee dealing with the evolution and current status and uses of proton beam radiation therapy (PBRT).
Filed under: Management, Treatment | Tagged: PBRT, proton beam, radiation therapy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site